Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BVP2
UPID:
GNL3_HUMAN
Alternative names:
E2-induced gene 3 protein; Novel nucleolar protein 47; Nucleolar GTP-binding protein 3; Nucleostemin
Alternative UPACC:
Q9BVP2; B2RDC1; Q5PU80; Q96SV6; Q96SV7; Q9UJY0
Background:
Guanine nucleotide-binding protein-like 3, also known as Nucleostemin, plays a crucial role in maintaining the proliferative capacity of stem cells. It achieves this by stabilizing MDM2, preventing its ubiquitination and subsequent proteasomal degradation. This protein is alternatively known as E2-induced gene 3 protein, Novel nucleolar protein 47, and Nucleolar GTP-binding protein 3.
Therapeutic significance:
Understanding the role of Guanine nucleotide-binding protein-like 3 could open doors to potential therapeutic strategies.